AGED Diagnostics develops a blood test utilizing targeted genomic sequencing to diagnose and stage liver disease, including NASH and fibrosis. This noninvasive assessment measures circulating genetic biomarkers to differentiate disease severity from benign conditions. The technology aims to enable earlier patient intervention, improving outcomes and reducing healthcare costs associated with late-stage liver disease.

eGlint has developed the ProteoNex™ technology, a miniature biosensing device that quantifies multiple biomarkers from a small blood sample in under five minutes without the need for sample purification. This technology addresses the urgent need for rapid and cost-effective diagnostics, particularly in critical conditions like sepsis, where timely intervention can significantly reduce mortality rates.